Mercurial AI provides personalized, AI-driven health insights for breast cancer patients by utilizing the latest scientific research and clinical guidelines to tailor treatment information to individual medical needs. This approach enhances decision-making for patients and physicians, increasing the likelihood of remission by 58%.
Funding
$220K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AMPASAFounders
Product
Problem
Breast cancer patients often struggle to navigate the overwhelming amount of complex medical information and treatment options available, leading to confusion and difficulty in making informed decisions. Generic treatment plans may not fully address individual patient needs and circumstances, potentially impacting the effectiveness of care.
Solution
Mercurial AI offers a personalized, AI-driven platform that delivers tailored health insights to breast cancer patients. By leveraging the latest scientific research and clinical guidelines, the platform matches the most relevant information to individual medical needs and circumstances. This approach aims to empower patients and physicians with enhanced decision-making capabilities, potentially increasing the likelihood of remission. The platform provides 24/7 access to information and support, ensuring patients receive timely answers to their questions and concerns.
Target Audience
The primary target audience is breast cancer patients seeking personalized information and support to navigate their treatment journey, as well as oncologists looking to enhance patient engagement and decision-making.
Features
- AI-powered health insights personalized for individual breast cancer diagnoses
- OncoChat virtual assistant trained on the same guidelines as oncologists
- Symptom tracking to monitor patient well-being
- Medication tracking to manage treatment adherence
- Lab result tracking to monitor disease progression and treatment effectiveness